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Novel dominant-negative prion protein mutants identified from a
randomized library
Abstract
Prion diseases are untreatable neurodegenerative disorders characterized by accumulation of PrP(Sc), an
aggregated isoform of the cellular prion protein (PrP(C)). We generated a library of PrP variants with
random mutations in the helix-3 domain and screened for dominant-negative mutants (DNMs) that
would inhibit replication of prions (the Rocky Mountain Laboratory strain) in infected N2a cells. Two of
the identified PrP mutants, Q167R and Q218K, were already known to counteract prion replication,
thereby validating the effectiveness of this approach. In addition, novel DNMs were found efficiently to
antagonize PrP(Sc) propagation in cells. In contrast to Q167R and Q218K, the newly identified DNMs
S221P and Y217C resided on the cell surface at a substantially lower level, suggesting that robust cell
surface display of DNM might not be a general prerequisite for efficient prion antagonism. The newly
identified DNMs point to useful target-selective therapeutic tools for the treatment of prion diseases.
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Abstract 
Prion diseases are untreatable neurodegenerative disorders characterized by accumulation 
of PrPSc, an aggregated isoform of the cellular prion protein, PrPC. We generated a library of 
PrP variants with random mutations in the helix-3 domain, and screened for dominant-
negative mutants (DNMs) that would inhibit replication of prions (RML strain) in infected N2a 
cells. Two of the identified mutants, Q167R and Q218K, were already known to counteract 
prion replication, thereby validating the effectiveness of this approach. In addition, novel 
DNMs were found to efficiently antagonize PrPSc propagation in cells. In contrast to Q167R 
and Q218K, the newly identified S221P and Y217C mutants resided on the cell surface at a 
substantially lower level, suggesting that robust cell surface display of DNM might not be a 
general prerequisite for efficient prion antagonism. The newly identified DNMs point to useful 
target-selective therapeutic tools for treatment of prion diseases. 
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Prions are the infectious agents causing transmissible spongiform encephalopathies (TSE) 
such as Creutzfeldt-Jakob disease in human and BSE in cattle. The central event in the 
pathogenesis of prion diseases is the ordered aggregation of misfolded isoform (PrPSc) of the 
cellular prion protein (PrPC). The structural and mechanistic basis of the aggregation remains 
elusive, primarily because a high-resolution structure of PrPSc is not available.  
A promising approach for gaining mechanistic understanding of the conversion of PrPC into 
PrPSc consists in the identification of amino-acid residue substitutions which interfere with the 
conversion. The resulting structural perturbations might shed light onto the motifs and 
determinants of the transformation of the cellular protein PrPC into an infectious agent. In the 
present study we present an approach based on functional screening for potent dominant 
negative PrP mutants from a focused PrP library. 
 
Materials and Methods 
Materials 
Reagents were obtained from Sigma, Fluka or Merck, unless stated otherwise. TBS-Tw (20 
mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween-20) was used as a buffer for the blocking buffer 
and for the incubation with antibodies during SCA and Western blot. PAA buffer [PBS/NP-40 
(2%)/Tween-20 (2%)] or RIPA buffer [PBS/NP-40 (1%)/sodium deoxycholate (0.25%)] were 
used for cell lysis. The generation of anti-PrP antibodies POM1, POM2 and POM3 was 
described elsewhere (Polymenidou et al., 2005). POM1 is directed against a discontinuous 
SDS-stable epitope on helix-1. POM2 and POM3 recognize, respectively, octapeptide 
repeats in the N-proximal region of PrP and residues 95-100 of murine PrP. 
Construction of the PrP mutant library 
Error-prone PCR by using nucleotide analogs was performed essentially as described 
previously (Zaccolo et al., 1996). The helix-3 library of murine PrP was generated on the 
DNA level by PCR (25 cycles) with primer pair CAAGGGGGAGAACTTCACC and 
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GTGCTGCTGGATCTTCTCCC (resulting in mutagenesis of residues Glu199 – Asp 226) in 
the presence of Taq DNA polymerase, dNTPs (0.2 mM) and dNTP analogs: 8-oxo-dGTP and 
dPTP (50 μM each). Full-length ORF for PrP was assembled by conventional overlapping 
PCR (25 cycles) with Vent DNA polymerase and dNTPs (0.2 mM). ORF encoding the PrP 
library or control PrP variants was cloned into expression vector pBMN-IRES-GFP (Swift et 
al., 1999). The resulting pBMN-PrP-IRES-GFP plasmid encodes for PrP variant and GFP 
(translated due to the IRES element in the mRNA transcript). Hereafter, we refer to the 
pBMN-IRES-GFP vector without any PrP-ORF inserted into the multiple cloning site as the 
‘NI’ (no insert plasmid) control. 
 
Scrapie cell-based assay (SCA) in 96-well format 
SCA used in the screening was modified, based on the original protocol initially developed 
for sensitive detection of scrapie prions in a cell-based bioassay (Klohn et al., 2003). 
Neuroblastoma N2a cells (the subclone N2aPK1 (Klohn, et al., 2003)), chronically infected 
with the RML scrapie prion strain, were seeded on 96-well cell culture plate in growth 
medium (OptiMEM with 10% FCS, Pen/Strep/GlutaMax) at density 1.2⋅104 cells per well, and 
transiently transfected with pBMN-PrP-IRES-GFP plasmid 2 h later. Mock-infected N2aPK1 
cells (treated with brain homogenate from non-inoculated mouse) were used as a control. 
Per one well, we routinely used 0.2 μg plasmid DNA and 0.5 μl Lipofectamine 2000 
(Invitrogen), each diluted in 25 μl of OptiMEM. The total volume of the growth medium was 
200 μl per well. Each PrP variant was tested in a triplet on a cell culture 96-well plate. Four 
days later, the growth medium was removed, and the cells were harvested in 200 μl 
PBS/EDTA (2mM). One aliquot of the cell suspension (80 μl) was used for determination of 
cell viability by using the MTS assay (CellTiter 96 Aqueous One Solution Cell Proliferation 
Assay Kit; Promega; absorbance readout at 490 nm; background signal was defined as the 
reading of samples devoid of cells), and another aliquot was used for determination of the 
PrPSc accumulation in transfected cells as follows. The cell suspension (80 μl) was mixed 
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with 80 μl proteinase K solution (60 μg/ml) in the PAA buffer, and incubated for 1 hour at 
37°C. All following incubation steps were carried out at room temperature. The digested cell 
lysate was transferred into the Immobilon-P plate (hydrophobic, high protein binding white 
plate; Millipore) pre-rinsed with 70% ethanol and PBS, and passed through the filter by 
applying vacuum. The plate was washed with PBS, and residual PK activity was stopped by 
incubation with PMSF (1 mM in PBS) for 10 minutes. PrPSc adherent to the filters was then 
denatured with guanidine thiocyanate (3 M in PBS) for 10 minutes. Wells were washed with 
PBS and incubated sequentially with blocking solution (Top-block) for 1 hour, the POM1 anti-
PrP antibody (0.4 μg/ml), and eventually with anti-murine IgG1-HRP conjugate (0.2 μg/ml; 
Zymed, Cat. No. 61-0120). Luminescence signal (relative luminescence units, RLU) was 
recorded by using “SuperSignal ELISA Pico chemiluminescent substrate” (Pierce; 100 μl per 
well). In a pilot experiments we found that the luminescence signal in the modified SCA 
reflected the percentage of the RML-infected cells in a sample containing a mixture of RML-
infected and non-infected N2a cells (data not shown). We concluded that the luminescence 
signal linearly reflected amount of PrPSc in our samples, and hence it was not necessary to 
use calibration (= serial dilution of purified PrPSc-standard) in our modified SCA. PrPSc 
accumulation (RLU) was normalized to the cell viability (A490 nm; see above) resulting in RLU´-
value for every single well. Average RLU´-value (ØRLU´) was determined from three (or 
more) technical replicas (=wells) on the 96-well plate. An example of raw data is given in 
Supplementary Figure 1. PrPSc accumulation for each tested library member was corrected 
for residual PrPC-signal, and then related to the corrected PrPSc -signal from the RML cells 
transfected with dummy vector (the NI-control) as follows: 
PrPSc accum.i = (ØRLU´i RML - ØRLU´ PrP/WT mock) / (ØRLU´NI RML - ØRLU´ NI mock) x 100 
 
SCA has been repeated in at least two additional independent experiments for all library 
members, which caused a decrease of the PrPSc accumulation in the cells by more than 50% 
related to the NI control. 
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Quantification of PrPSc accumulation in transfected N2a/RML cells by Western blot 
The N2a cells, chronically infected with the RML prions, were seeded on a 25-cm2 cell 
culture T-flask, and transiently transfected as described above (a scale-up factor 30, 
compared to the 96-well plate). Three days later, the cells were harvested, and the pellet 
was resuspended in 120 μl of the RIPA buffer. The cell lysate was cleared by centrifugation 
at 2000 g for 3 minutes, adjusted to protein concentration 5 mg/ml (determined by BCA 
assay, Pierce), and incubated with PK (20 μg/ml) at 37°C for 30 minutes. Non-digested 
aliquot was kept on ice. The samples were then incubated with NuPAGE sample buffer 
(Invitrogen; supplemented with 100 mM DTT) for 5 minutes at 95°C. Proteins in the sample 
(25 μg per lane) were separated on a pre-cast NuPAGE 12% Bis-Tris gel, and blotted onto 
nitrocellulose membrane. We used anti-PrP antibody POM3 (5 μg/ml) for detection of PrPSc 
because: i- its epitope (residues 95-100 in murine PrP) remains intact during the PK-digest, 
and ii- recognition of PrP by the POM1 antibody used for the primary screening was found 
later to be affected in mutants containing mutation Y217C (data not shown). Sample aliquots 
not digested with PK were probed by Western blot by using anti-GFP antibody (100 ng/ml; 
Roche Applied Science) or anti-β-actin antibody (100 ng/ml; Chemicon) in order to assess 
transfection efficiency in N2a cells, and protein loading on the gel, respectively. Rabbit anti-
murine IgG1-HRP conjugate was used as a secondary antibody. Light development using 
“SuperSignal West Pico chemiluminescent substrate” (Pierce) was detected by a CCD 
camera, and intensity of protein bands was quantified by TINA software (Raytest). 
Quantification of PrP expression in HpL3-4 cells by Western blot 
Immortalized HpL3-4 cells derived from hippocampus of Prnp-/- mouse (Kuwahara et al., 
1999) were seeded on 12-well cell culture plate at density 1.8⋅105 cells per well, and 
transiently transfected as described above (a scale-up factor 5, compared to the 96-well 
plate). Twenty four hours later, the cells were harvested, resuspended in 50 μl of the PAA 
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buffer supplemented with protease inhibitor cocktail (0.5%; Sigma, Cat. No. P-8340), and 
cleared by centrifugation at 2000 g for 3 minutes. An aliquot of the cell lysate was used for 
protein determination by the BCA assay. The cell lysates was mixed with the NuPAGE 
sample buffer, and incubated for 5 minutes at 95°C. The Western blot was performed as 
described above. Here, anti-PrP antibody POM2 (0.4 μg/ml) was used as a primary antibody 
for detection of full-length PrP because POM2 has a very high avidity due to its multiple 
binding of octa-repeats in the N-terminus of PrP.  For quantification, signals corresponding to 
the amount of detected PrP and GFP (co-expressed due to the IRES-element) were 
normalized to the signal corresponding to β-actin, and then the PrP signal was normalized to 
the GFP signal (compensation for variation in transfection efficiency among the cell 
samples). Expression level of DNMs was related to PrP WT. 
Quantification of cell surface expression of PrP in HpL3-4 cells by flow cytometry 
HpL3-4 cells were seeded on 12-well cell culture plate, and transiently transfected, as 
described above. Twenty four hours after the transfection, the cells were harvested, and 
stained with the conjugate of anti-PrP antibody POM2 with Cy5. PBS/FCS (1%)/EDTA (10 
mM)/NaN3 (0.1%) was used for the antibody dilution and subsequent washes. The incubation 
with the POM2-Cy5 and washes were carried out at 4°C in order to prevent internalization of 
PrP in the cells. Data were acquired on an instrument “BD FACS Calibur”. We gated on live 
and GFP-positive cells, and the mean Cy5 fluorescence was used for quantification of the 
PrP expression level. Signal from the cells transfected with the NI control was used for offset 
of the background.
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Results 
Design and generation of a focused PrP library. 
We set out to generate a broad range of amino acid residue substitutions which might 
interfere with the conversion of PrP. Since random mutagenesis is an established tool for 
extensive exploration of the sequence space in proteins (Drummond et al., 2005, Hermes et 
al., 1990), we opted to produce a library of mutants randomized in the open reading frame of 
murine Prnp by error-prone PCR. The library was then screened for dominant negative 
mutants (henceforth termed DNMs) of PrP. A number of methods is available for in vitro 
conversion of PrPC into a PrPSc-like state (Kocisko et al., 1994, Saborio et al., 2001) yet none 
of these methods has been validated for the discovery of dominant-negative mutants. While 
more cumbersome and not easily amenable to forward genetics, cell culture assays were 
deemed more suitable for this purpose because of their sensitivity and precise quantitative 
responses (Klohn, et al., 2003). Therefore, we decided to screen a focused small-size PrP 
library for DNMs in a functional, albeit low-throughput screening in cells.  
It has been observed that N-proximal truncations of PrP (deletion of residues 23-88) did not 
prevent PrPSc propagation in cell culture (Rogers et al., 1993) and in mice (Fischer et al., 
1996), suggesting that the N-terminus does not play a crucial role in the PrP conversion. In 
contrast, PrP-mutations, identified due to naturally occurring ‘prion-resistant’ polymorphism in 
sheep and human, were found to possess potent dominant-negative properties. In particular, 
the substitutions Q167R in the loop connecting β-sheet 2 and helix-2 (loop ‘L1’, residues 
165-173), and Q218K in the helix-3 (residues 199-226), were found to strongly inhibit PrPSc 
propagation in cell culture and in transgenic mice (Kaneko et al., 1997, Perrier et al., 2002).  
We decided to analyze a series of random mutations within the helix-3 domain. We predicted 
that the replacement of many of its residues might result in disruption of stabilizing 
intrahelical and intramolecular hydrogen bonds and salt bridges, thereby bringing about 
structural perturbations in the PrP molecule that may be a prerequisite for interference with 
PrPSc aggregation. The length of helix-3 (28 residues) was expected to allow for satisfactory 
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residue substitution coverage by screening ~100 members of a library with a mutational load 
of ~1-2 mutations per clone. Hence the above strategy would result in testing ~5 
substitutions of each residue within the helix-3. 
Noteworthy, we opted not to introduce a tag for the 3F4-antibody (Kascsak et al., 1987) (the 
antibody recognizes murine PrP with mutations L108M/V111M) often used to distinguish 
endogenous and heterologous PrP in murine neuroblastoma cells. It has been reported that 
the murine PrP/L108M/V111M heterologously expressed in the N2a cells is not converted 
per se into PrPSc, and it can antagonize accumulation of wild-type PrPSc  in the N2a cells 
(Priola et al., 1994). Similarly, we have observed that PrP/L108M/V111M, in contrast to wild-
type PrP, heterologously expressed in chronically-infected N2a cells did not contribute to the 
generation of PrPSc in the cells (data not shown). If the additional L108M/V111M-mutations 
were introduced into the sequence of the PrP/helix 3-library members, interpretation of the 
dominant-negative effect would be considerably compromised. 
The library of PrP randomized in the helix-3 has been generated on the DNA level by error-
prone PCR, as described in Materials and Methods. We analyzed sequences of 40 randomly 
picked clones in order to characterize the quality of the library. As expected, the vast majority 
of nucleotide substitutions consisted of the transitions A↔G and T↔C. The rate of mutations 
was ~3% at the level of DNA, and the mutational load was 2±2 mutations per clone. Most of 
the analyzed clones (97%) encoded full-length PrP. The vast majority (~90%) of all analyzed 
mutations were found within the gene region that encodes the helix-3. We conclude that 
quality of the generated library was suitable for our screening purpose.  
 
Screening of the PrP library by scrapie cell-based assay. 
The neuroblastoma N2a cells (Race et al., 1987) provide an attractive cell culture model of 
the chronic propagation of scrapie-derived prions in vitro, and have been exploited in many 
paradigms for high-throughput screens of small molecular weight anti-prion compounds 
(Kocisko and Caughey, 2006). Prion propagation in the infected cells is usually stable for 
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several months, and does not seem to affect cell viability. We decided to use scrapie cell 
assay (hereafter SCA) (Klohn, et al., 2003) suitable for handling of N2a cells in the 96-well 
format. N2a cells (subclone PK1) chronically infected with RML prions (hereafter N2a/RML) 
were transfected with plasmids encoding individual members of the PrP library, and several 
days later the amount of PrPSc accumulated in the cells was assessed.  
We modified SCA conditions in order to ensure efficient removal of PrPC which interferes 
with the detection of PrPSc. This is an important consideration in our set-up because the 
transfected N2a cells express endogenous PrP under the control of the authentic murine PrP 
promoter, and also a PrP variant under the control of a viral promoter present in the 
expression vector. In particular, we found that it was crucial to increase the PK concentration 
from 0.5 to 30 μg/ml (final concentration; data not shown for the optimization of SCA). Under 
these optimized conditions, signals yielded by N2a/RML cells transfected with the NI control 
plasmid were ca. 10-fold higher than those of mock-infected N2a cells transfected with 
plasmid encoding wild-type PrP. This indicates that the detection of PrPSc was not 
compromised by the overexpression of PrP in transfected cells.  
We screened 140 library members using the optimized SCA (raw data for a representative 
SCA are shown in Suppl. Figure 1). Since the screen was aimed at identifying potent DNMs 
which would significantly inhibit PrPSc propagation in the cells, we focused on analysis of PrP 
mutants which caused more than 50% decrease of PrPSc accumulation in N2a/RML cells 
when compared to a NI control (Figure 1). The mutations within the sequence of the helix-3 
domain in these DNMs were distributed across the entire domain. In addition to the positive 
control (PrP/Q218K), we identified three other single mutations among the DNMs: 
PrP/Q167R, PrP/S221P and PrP/Y225C. Q167 does not reside in the helix-3, but in the L1 
loop which had not been intentionally mutagenized. Hence the Q167R mutation was 
incidentally introduced during assembly of the PrP gene by PCR. All other DNMs contained 
multiple mutations. We introduced mutations K203R, T215A, Y225H, or Y217C which were 
frequently found in several multiple DNMs (Figure 1) into the PrP gene, and evaluated the 
effect of these single mutants in SCA. We found that PrP/Y217C is a very potent DNM, 
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whereas the inhibitory effects of the mutants PrP/Y225H and PrP/T215A were more 
moderate. The mutant PrP/K203R (with a basic residue substituted for another basic 
residue) behaved in SCA like PrP WT (Figure 1).  
We tested in the SCA also rabbit and canine PrP, which may be particularly resilient to 
conversion into PrPSc given that rabbits and dogs are resistant to various prion strains (Loftus 
and Rogers, 1997, Lysek et al., 2004). PrPSc propagation in N2a/RML cells transfected with 
these PrP variants was similar to that observed in NI control cells (85±15 % and 93±5 % for 
rabbit and canine PrP, respectively; N=2), suggesting that rabbit PrP and canine PrP were 
indeed not converted into PrPSc form, but on the other hand indicating that these PrP variants 
do not antagonize propagation of RML prions. 
In order to confirm the above results from the screening, we analyzed the effect of the most 
potent DNMs on clearance of RML in the cells by Western blot. In agreement with the SCA 
results, transfection of N2a/RML cells with PrP/Q167R, PrP/Y217C, PrP/S221P, 
PrP/Y217C/Y225H/D226G, or PrP/M212L/Q218R/S221P resulted in substantial (70-90%) 
reduction of PrPSc, whereas transfection of the N2a/RML cells with a plasmid encoding PrP 
WT resulted in ~3-fold increase in PrPSc accumulation (Figure 2). Notably, the prevalence of 
transfected N2a/mock or N2a/RML cells was only ~30-50%. This suggests that DNM 
expression, in addition to clearing prions from transfected cells, interferes with prion 
propagation also in non-transfected N2a/RML cells by a mechanism which remains to be 
elucidated. 
Expression of selected dominant negative mutants in HpL3-4 cells. 
The biogenesis of the most potent DNMs was characterized in PrP-deficient HpL3-4 cells, 
which were originally derived from the hippocampus of a Prnp-/- mouse (Kuwahara, et al., 
1999). Under these conditions, the folding and cellular trafficking of the tested PrP variants 
cannot be modified by the co-expression of WT PrPC, as may be the case in N2a cells. 
Western blot analyses by using the anti-PrP antibody POM2, which binds octa-repeats in the 
N-terminus of PrP (Polymenidou, et al., 2005), showed that the overall expression level and 
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expression profile (mobility of PrP glycoforms) of PrP/Q167R, PrP/Y217C, PrP/Q218K, 
PrP/S221P, PrP/Y217C/Y225H/D226G, and PrP/M212L/Q218R/S221P was similar to that of 
transfected PrP WT (Figure 3a). We detected a tendency for PrP/Q218K to be expressed at 
somewhat higher levels than PrP WT; however, expression levels of PrP WT and tested 
DNMs did not differ significantly (Figure 3b).  
Mature PrP molecules are normally attached to the plasma membrane via 
glycosylphosphatidylinositol (GPI) anchor, and localized in lipid rafts (Stahl et al., 1987). We 
therefore wondered whether the selected DNMs stably reside on the cell surface. In order to 
address this question, we opted to quantify PrP localized on the cell surface by flow 
cytometry. HpL3-4 cells were transfected with DNM-encoding plasmids, and stained with 
conjugate of the anti-PrP-antibody POM2  with the Cy5 fluorophore. Staining was carried out 
at 4°C in order to prevent internalization of the label prior to flow cytometric analysis. The 
data reported in Figure 4 suggest that PrP/Q218K and PrP/Q167R reside on the cell surface 
at a similar level as PrP WT. In contrast, the surface presence of other DNMs (PrP/Y217C, 
PrP/S221P, PrP/Y217C/Y225H/D226G, and PrP/M212L/Q218R/S221P) was much lower 
compared to the PrP WT.  
PrPC is known be to constitutively internalized (Kaneko et al., 1997, Prado et al., 2004). It is 
plausible that the DNMs, which seem to be not abundant on the cell surface, are properly 
targeted to the cell surface; however, due to their destabilized structure they are internalized 
in a substantially faster rate than wild-type PrPC. An analogous mechanism has been 
previously demonstrated for several mutated G protein-coupled receptors which also reside 
in lipid rafts (Ott et al., 2004). Taken together, it seems that stable localization on the cell 
surface of the selected DNMs is not a prerequisite for the prion antagonism. In fact, fast 
internalization into early endosomes may enhance prion antagonism for, at least, some of 
the selected DNMs since it was suggested that PrP is likely to be converted under the low 
pH conditions found in endosomes (Borchelt et al., 1990, Kaneko, et al., 1997). 
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Discussion 
In this study, we screened for PrP mutants that would inhibit prion propagation in prion-
infected N2a cells. Antagonistic effect of heterologous (mutated or chimeric) PrP-molecules 
on prion propagation in cell culture was initially reported by Priola and colleagues (Priola, et 
al., 1994). In following mutagenesis studies, researchers tested effects of naturally occurring 
protective polymorphisms (Crozet et al., 2004, Kaneko, et al., 1997, Zulianello et al., 2000), 
glutamine residue substitutions (Atarashi et al., 2006), or reversal of charged residues in the 
helix-1 (Norstrom and Mastrianni, 2006) on PrP conversion. Here, we reasoned that the 
structural determinants of prion propagation are very poorly understood, and therefore 
rational predictions about the impact of individual mutations might be treacherous if not 
impossible. For these reasons we opted to undertake an unbiased effort by randomizing the 
sequence of a defined region of PrP, helix-3 within the carboxy-proximal globular domain of 
PrP.  
We found a relatively broad distribution and various kinds of amino acid residue substitution 
in the selected dominant negative mutants (DNMs). Some of these individual mutations, in 
particular Q167R, Y217C, Q218K and S221P, had a pronounced effect on prion propagation. 
While PrP/Q167R and PrP/Q218K had been already identified as potent DNMs based on the 
natural ‘prion-resistant’ polymorphism in ovine and human PrP, respectively (Kaneko, et al., 
1997), the Y217C and S221P mutations point to hitherto unreported hot spots that may be 
crucial for the process of PrP conversion. It is conceivable that the additional cysteine 
residue in the PrP/Y217C mutant, possibly affecting the formation of the conserved S-S bond 
during the folding of PrP, and the S221P replacement within the helix-3, which can cause a 
break in the helix, have effect on PrP misfolding and aggregation resulting in the interference 
with the PrP conversion in the presence of wild-type PrPC in the cells.     
How do DNMs exert their anti-prion effects? The nucleation hypothesis of prion propagation 
(Aguzzi and Weissmann, 1997, Jarrett and Lansbury, 1993) provides a very simple model for 
their action. In this framework, prions consist essentially of highly ordered, oligomeric 
aggregates of ca. 15-20 PrPSc molecules (Silveira et al., 2005). In many similar paradigms of 
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nucleation, such aggregates grow appositionally at one end by addition of individual 
monomers. Here, DNMs may yield ‘defective’ monomers that can be recruited by existing 
seeds, yet do not have reactive interface necessary for the recruitment of further monomers. 
Hence DNMs might effectively “cap” seeds and quench their infectious potential (Horiuchi et 
al., 2000).  
Testable structural models of DNMs, derived e.g. from nuclear magnetic resonance studies 
and/or from folding simulations, are likely to assist in the elucidation of the mechanism of the 
PrP conversion at the atomic level, and may help devising even more powerful DNMs based 
on rational predictions rather than random mutagenesis. 
However, several alternative models of conversion inhibition are thinkable and would be 
compatible with the results reported above. For example, it is possible that DNMs affect prion 
propagation by competing with PrPC for a putative cofactor. The extraordinarily inefficient 
generation of prion infectivity in vitro from chemically defined constituents (Legname et al., 
2004) suggests the existence of such cofactors in cells and in tissues. Circumstantial 
evidence suggests that the site of PrP conversion, and possibly of any hypothetical auxiliary 
factor (Kaneko, et al., 1997) may be congruent with caveolae-like domains of the cell surface 
or endosomes (Kaneko, et al., 1997, Nunziante et al., 2003). However, other cellular 
localizations are by no means excluded, and the auxiliary factors may encompass also non-
proteinaceous polyanionic molecules such as nucleic acids (Deleault et al., 2007).  
As a next step, it will be of interest to ascertain the potential of the newly discovered DNMs 
to inhibit PrPSc propagation in vivo. For any therapeutic application to be successful, it will be 
crucial that prion antagonists efficiently diffuse within the CNS and exert their effects non-
cell-autonomously. Encouragingly, recombinant non-glycosylated PrP/Q218K administered 
in a soluble form (without the GPI anchor) was found to antagonize PrPSc propagation in 
prion-infected N2a cells (Kishida et al., 2004). However, another study found that cell-
autonomous expression and tethering by a GPI anchor is important for efficient PrPSc 
antagonism by PrP/Q218K in prion-infected N2a cells (Zulianello, et al., 2000). We made 
similar observations when selected DNMs were expressed in a soluble form, without the GPI 
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anchor, in N2a/RML cells (data not shown). Maybe the GPI anchor is important for efficient 
targeting of DNM into endosomes, where PrPC is presumed to be converted into PrPSc. If so, 
this requirement could be fulfilled by the use of molecular targeting signals for transport of 
DNMs into endosomes. Efficient targeting signals may be, for instance, derived from the 
internalization domain of bacterial or plant toxins (Medina-Kauwe, 2007, Sandvig and van 
Deurs, 2002).  
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Figure Legend 
 
Figure 1. Accumulation of PrPSc determined by SCA for N2a/RML cells transfected 
with plasmid encoding PrP variant. N2a/RML cells were transfected with the pBMN-PrP-
IRES-GFP plasmid, harvested 4 days later, and treated with PK (30 μg/ml) for detection of 
PrPSc in SCA (see Materials and Methods). The values (average and standard deviation from 
N independent experiments) were calculated as a ratio of luminescence signals, normalized 
to the number of viable cells, for a tested PrP variant and the NI control (set as 100%). 
Values in the upper panel are shown only for the selected PrP library members, which 
caused a decrease in the PrPSc accumulation of more than 50%, related to the NI control. In 
each run of the SCA, we used plasmids encoding PrP WT or PrP/Q218K as controls. In the 
lower panel, values are shown for single PrP mutants, which were constructed after the 
primary screen, based on mutations frequently found in DNMs, listed in the upper panel. 
 
Figure 2. Accumulation of PrPSc is decreased in N2a/RML cells transfected with 
selected DNMs, as determined by Western blot. 
N2a cells, chronically infected with RML (annotated as ‘RML’ cells), and mock-infected N2a 
cells (annotated as ‘mock’ cells) were transfected with the pBMN-PrP-IRES-GFP plasmid, 
harvested 3 days later, and treated with PK (20 μg/ml) for detection of PrPSc. Western blot 
data representative of two independent transfections are shown. Normalized value for the NI-
control (100%) did not lie within the confidence interval determined for each of the five tested 
PrP-mutants (N=2). Thus the effect of each tested DNM was significantly distinct from the 
effect of the NI-control. The tested DNMs are annotated as follow: M1: PrP/Q218K, M2: 
PrP/Q167R, M3: PrP/Y217C, M4: S221P, M5: PrP/Y217C/Y225H/D226G. WT relates to 
wild-type PrP and NT relates to non-transfected cells. 
 
Figure 3. Overall expression of selected DNMs in transfected HpL3-4 cells, determined 
by Western blot. A: The cells were transiently transfected with the pBMN-PrP-IRES-GFP 
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plasmid, and harvested 24 hours later. The tested DNMs are annotated as follow: M1: 
PrP/Q218K, M2: PrP/Q167R, M3: PrP/Y217C, M4: S221P, M5: PrP/Y217C/Y225H/D226G. 
WT relates to wild-type PrP and NT relates to non-transfected cells. B: PrP expression level 
(related to PrP WT) determined in 4 independent transfection experiments. The confidence 
interval (at 95% probability level) is defined as average value ± 1.96  standard deviation. 
 
Figure 4. Cell surface expression of selected DNMs in transfected HpL3-4 cells, 
determined by flow cytometry. The cells were transiently transfected with the pBMN-PrP-
IRES-GFP plasmid, and harvested 24 hours later. For the analysis of PrP expression on the 
cell surface, gates were set on live and GFP-positive cells. Values are based on 3 
independent transfection experiments. NI relates to the cells transfected with the NI control 
plasmid. 
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Supplementary Figure 1. Example of raw data from SCA. N2a cells (mock-infected or 
RML-infected) were plated in 96-well plates and transiently transfected with plasmid 
encoding PrP variants. Four days later, cells in the plates were processed and analyzed. 
Bars and error bars represent average values and standard deviations, respectively, of 
triplicate determinations. A: Cell viability determined by MTS assay. All values were 
corrected for the background (defined as the signal in a sample devoid of cells). B: PrPSc 
accumulation in cells determined after PK digestion by using antibody POM1.  
 
 
 
 
 
